Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
VtVGz8hkabTTJMsv
Listen
